Gene that helps mosquitoes fight off malaria parasite identifiedOctober 25, 2005Researchers have identified a gene in mosquitoes that helps the insects to fight off infection by the Plasmodium parasite, which causes malaria in humans. Anopheles mosquitoes transmit the malaria parasite to nearly 550 million people worldwide each year with these cases resulting in more than 2 million deaths annually. The protective gene was identified in a study conducted by a team of investigators from the Johns Hopkins Bloomberg School of Public Health's Malaria Research Institute, the Imperial College of London and the University of Texas Medical Branch. It will be published in the Online Early Edition of the Proceedings of the National Academy of Sciences the week of October 24. The malaria-causing Plasmodium has a complex life cycle. Mosquitoes become infected with the parasite when they draw blood from humans who have malaria. As the parasite matures, it moves from the mosquito's midgut to its salivary glands. Once in the salivary glands, the Plasmodium can be injected into another human when the mosquito feeds again. In the study, the researchers determined that the SPRN6 gene, which is normally switched off in Anopheles stephensi and Anopheles gambiae mosquitoes, is switched on when they are infected with the malaria parasite. To determine the function of SPRN6, the researchers deactivated the gene in the mosquitoes through a process called RNA interference. They observed that the number of parasites that developed in Anopheles stephensi mosquitoes increased three-fold when the gene was knocked out. In Anopheles gambiae mosquitoes, removing the SPRN6 gene delayed the process of parasite lysis, whereby the mosquito rids itself of the parasite. "This study furthers our knowledge of the malaria-parasite lysis in mosquitoes. It may help provide better tools for controlling the disease in the future," said lead author Eappen G. Abraham, PhD, research associate in the Department of Molecular Microbiology and Immunology and the Malaria Research Institute at the Bloomberg School of Public Health. "These results provided new insights into how the mosquito defends itself from the malaria parasite. More research is needed, but we plan to apply this knowledge in the development of new approaches to control the disease," said co-author Marcelo Jacobs-Lorena, PhD, a professor in the Department of Molecular Microbiology and Immunology and the Malaria Research Institute at the Bloomberg School of Public Health. Abraham and Jacobs-Lorena are developing a transgenic mosquito in which the SPRN6 gene is permanently switched on, in an effort to create a mosquito that would be immune to the Plasmodium parasite. They believe that such a mosquito could help disrupt the transmission of malaria to humans. "An immune-responsive serpin, SRPN6, mediates mosquito defense against malaria parasites" was written by Eappen G. Abraham, Sofia Pinto, Anil Ghosh, Dana L. Vanlandingham, Aidan Budd, Stephen Higgs, Fotis C. Kafatos, Marcelo Jacobs-Lorena and Kristin Michel. Abraham, Ghosh and Jacobs-Lorena are with the Johns Hopkins Bloomberg School of Public Health. Pinto, Budd, Kafatos and Michel are with the European Molecular Biology Laboratory in Heidelberg, Germany and the Imperial College of London. Vanlandingham and Higgs are with the Department of Pathology at the University of Texas Medical Branch. Johns Hopkins University Bloomberg School of Publi |
|||||||||||||||||||||
| Related Malaria Parasite Current Events and Malaria Parasite News Articles Small nanoparticles bring big improvement to medical imaging If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. Media availability: The role of biomedical research in malaria eradication Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year. UM School of Medicine researchers find extreme genetic variability in malaria parasite Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world. New research confirms potential deadly nature of emerging new monkey malaria species in humans Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. Scientists report original source of malaria Researchers have identified what they believe is the original source of malignant malaria: a parasite found in chimpanzees in equatorial Africa. Unique immunization method provides insights about protective anti-malaria immune response In this week's New England Journal of Medicine, scientists in Singapore, The Netherlands and France report that they have developed a novel immunization method that will induce fast and effective protection in humans against the life-threatening malaria parasite, Plasmodium falciparum, which infects 350 to 500 million people world-wide and kills over one million people each year. First genetically-engineered malaria vaccine to enter human trials Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. Vaccine Blocks Malaria Transmission in Lab Experiments Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine. Breakthrough in combating the side effects of Quinine Discovered back in the 1600s quinine was the first effective treatment in the fight against malaria - and it continues to be a commonly used treatment against this devastating disease. More Malaria Parasite Current Events and Malaria Parasite News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||